Swedish Orphan Biovitrum Targets SEK 55bn Revenue by 2030

Swedish Orphan Biovitrum hosted its Capital Markets Day on February 18, 2026, where senior management presented an updated strategy and a new mid-term outlook. The company aims to achieve SEK 55 billion in revenue by 2030, effectively doubling its 2025 revenue of SEK 28 billion, and targets an adjusted EBITA margin in the upper 30s percentage of revenue by 2030. This growth is expected to be driven by six major product launches, including Swedish Orphan Biovitrum===Efanesoctocog alfa, Swedish Orphan Biovitrum===Emapalumab, Swedish Orphan Biovitrum===Pegcetacoplan, Swedish Orphan Biovitrum===Olezarsen, Swedish Orphan Biovitrum===NASP, and pozdeutinurad, across haematology, immunology, and specialty care. Swedish Orphan Biovitrum also highlighted its scientific leadership in areas like uncontrolled and progressive gout, severe hypertriglyceridemia, and precision medicine in sepsis, with promising data for empalumab. The company plans to maintain R&D expenses between 11-14 percent of sales.